BiVictriX Therapeutics (LON:BVX) Trading Up 17.6% – Here’s What Happened

BiVictriX Therapeutics Plc (LON:BVX) shares were up 17.6% on Tuesday . The stock traded as high as GBX 10 ($0.13) and last traded at GBX 10 ($0.13). Approximately 1,538,020 shares were traded during mid-day trading, an increase of 1,320% from the average daily volume of 108,326 shares. The stock had previously closed at GBX 8.50 ($0.11).

BiVictriX Therapeutics Stock Performance

The stock has a market capitalization of £8.25 million, a P/E ratio of -250.00 and a beta of -0.73. The firm has a 50-day moving average of GBX 9.26 and a 200 day moving average of GBX 10.98. The company has a quick ratio of 7.49, a current ratio of 4.40 and a debt-to-equity ratio of 8.81.

Insider Buying and Selling

In other news, insider Robert Edward Hawkins bought 20,000 shares of BiVictriX Therapeutics stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average cost of GBX 7 ($0.09) per share, with a total value of £1,400 ($1,817.71). 42.56% of the stock is owned by company insiders.

About BiVictriX Therapeutics

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.